Clinical Trial Update: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) [Phase 2]

View source ↗

Summary

Phase 2 trial exploring neoadjuvant XL-092 (zanzalintinib) with pembrolizumab (Keytruda) for surgically resectable, HPV-negative oral cavity squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• XL-092 (zanzalintinib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Status: NOT_YET_RECRUITING